T1	Participants 35 106	previously treated, PD-L1-positive, advanced non-small-cell lung cancer
T2	Participants 363 449	patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer.
T3	Participants 513 557	202 academic medical centres in 24 countries
T4	Participants 559 671	Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
T5	Participants 1331 1344	1034 patients
T6	Participants 3177 3262	patients with previously treated, PD-L1-positive, advanced non-small-cell lung cancer
